Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Finance · ·
$9.72
▼ $0.02 (-0.2%)
Market data updated: 09/14 01:34 PM
News analyzed: 09/14/2026
Market Cap
Not available
Day Range
$9.71 - $9.76
52-Week Range
$8.80 - $10.20
Beta
—
Next Earnings
—
+2.9% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 3/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 1.1% of price
Risk
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.07 (3y annualized return 1.4% / max drawdown 20.7%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 5 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 5
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
The investor score of 48 and MODERATE rating for GRX reflect a balanced mix of technical strengths and risk concerns. On the positive side, the stock trades above both its 50‑day and 200‑day moving averages, indicating recent price support and an uptrend over the longer horizon. The 0.8% outperformance versus the index over the last three months adds a modest bullish bias, while an ATR of 1.1% suggests moderate volatility that is not extreme. However, these gains are offset by several cautionary signals. The Calmar ratio of 0.11 (annualized return of 2.3% versus a 20.7% maximum drawdown) points to weak risk‑adjusted performance, and the MACD histogram is negative, signaling falling momentum. Additionally, the price sits below the SAR point, which typically marks a downtrend, and the %K oscillator at 2.6 indicates an oversold condition that may limit further declines. The 12‑day ROC of -0.9% reinforces short‑term bearish pressure. News remains neutral with a single distribution announcement, and the technical score of 46, news score of 50, and risk score of 50 collectively pull the overall assessment toward a moderate stance. The combination of solid average support, modest recent gains, and pronounced downside warnings justifies the current investor score and rating.
The technical category shows the price above the 50‑day and 200‑day averages, but also includes a negative MACD histogram, an RSI of 48.3 indicating weak bias, and an oversold %K of 2.6.
These mixed signals create uncertainty about near‑term direction.
News includes a neutral distribution announcement from Gabelli Healthcare & WellnessRx Trust for the third quarter.
A neutral news item does not provide a strong sentiment driver for the stock.
Risk metrics feature an ATR of 1.1% of price and a low Calmar ratio of 0.11 (2.3% 3‑year return vs 20.7% max drawdown).
The modest volatility combined with weak risk‑adjusted returns raises caution for investors.
StockIQ conclusion
GRX’s moderate investor score stems from a blend of technical resilience and heightened risk concerns. While the stock benefits from trading above long‑term moving averages and a slight 3‑month outperformance, it faces headwinds from a low Calmar ratio, negative momentum indicators, and a downtrend signal under the SAR. Neutral news provides no upside catalyst, leaving the risk‑adjusted profile as the primary driver of the rating. The current stance reflects balanced but cautious market expectations.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
39
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
33
Risk
50
Sentiment
50
Fundamental
No data available
Institutional
83
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of the Gabelli Healthcare & Wellness Trust has primarily focused on its financial updates, specifically the declaration of a third-quarter distribution of **$0.17 per share** on August 12, 2026. No other notable events or recurring themes were highlighted in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about The Gabelli Healthcare & Wellness Trust Common Shares of Beneficial Interest. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 1 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
12
🎯 Conviction (vs. Emotion)
50
Psychology
47
Fundamentals
—
Technical
33
Valuation
—
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+6%
Market Narrative
39
Fundamental Reality
50
Narrative Gap
-11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
GRX’s psychology is dominated by **anchoring**, as traders appear fixated on the 2.6% resistance gap, ignoring weaker momentum and peer underperformance. The **narrative-reality gap** (-7) hints at a disconnect: traders may overvalue recent resistance despite neutral sentiment (50/100) and modest volatility. **Herding** (42) suggests some alignment with peers, but the lack of FOMO or euphoria signals caution. The key question: will traders break free from resistance anchoring, or will the gap widen as momentum remains weak?
Updated: 09/08/2026, 03:50 PM
What could change this?
📈 3D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 96/100
🔴 Weakest match
Jack Schwager — 42/100
🗣️ Why do they disagree?
The stark divide in verdicts for GRX reflects a tension between growth-oriented, patient investing and more cautious or cyclical frameworks. Methodologies like **Morgan Housel (95)** and **Samuel Nelson (84)**—which favor quiet compounders and favorable cycle positions—view the stock as a compelling long-term hold, while **Thorstein Veblen (80)** and **Gerald Loeb (68)** see it as a reasonable, value-aligned opportunity with controlled risk. In contrast, **Jesse Livermore (42)** and **Jack Schwager (25)**—rooted in trend-following and disciplined setups—reject it outright, dismissing it as either counter-trend or lacking a clear entry point. Meanwhile, **Howard Marks (67 vs. 58 in cycle mode)** splits the difference, acknowledging risk but downplaying cycle-specific red flags, while **Efficient Market proponents (53)** dismiss it as unworthy of active selection over passive indexing. The disconnect between high-scoring growth methodologies and low-scoring trend traders underscores whether GRX is a stealthy winner or a speculative gamble.
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 100
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 95
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 94
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 68
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 68
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 61
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 15.6.2026 | $0.170 |
| 17.3.2026 | $0.170 |
| 12.12.2025 | $0.170 |
| 16.9.2025 | $0.170 |
| 13.6.2025 | $0.170 |
| 17.3.2025 | $0.150 |
| 13.12.2024 | $0.150 |
| 16.9.2024 | $0.150 |
| 13.6.2024 | $0.150 |
| 13.3.2024 | $0.150 |
| 14.12.2023 | $0.150 |
| 14.9.2023 | $0.150 |
Sentiment based on basic keywords (not AI) — 0 positive, 1 neutral, 0 negative out of the last 1 articles.
GlobeNewswire · 12.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for The Gabelli Healthcare & Wellness Trust Common Shares of Beneficial Interest (GRX) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for GRX specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
GRX's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 1.1% of price; Price is above the 200-day average; +2.4% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Calmar: 0.07 (3y annualized return 1.4% / max drawdown 20.7%); Price is below the 50-day average; MACD histogram is negative — falling momentum.
Yes — GRX has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 19 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Saba Capital Management, L.P. | Open Market Purchase | 3.9.2026 | 500 | +500 | $10.08 |
| Saba Capital Management, L.P. | Open Market Purchase | 27.8.2026 | 4,340 | +4,340 | $10.05 |
| Saba Capital Management, L.P. | Open Market Purchase | 21.8.2026 | 7,087 | +7,087 | $10.13 |
| Saba Capital Management, L.P. | Open Market Purchase | 19.8.2026 | 24,102 | +24,102 | $10.13 |
| Saba Capital Management, L.P. | Open Market Purchase | 14.8.2026 | 1,203 | +1,203 | $9.86 |
| Saba Capital Management, L.P. | Open Market Purchase | 11.8.2026 | 200 | +200 | $9.93 |
| GABELLI MARIO J | Open Market Purchase | 12.1.2026 | 1,010 | +1,010 | $9.58 |
| GABELLI MARIO J | Open Market Purchase | 12.1.2026 | 3,800 | +3,800 | $9.58 |
| GABELLI MARIO J | Open Market Purchase | 8.1.2026 | 990 | +990 | $9.58 |
| GABELLI MARIO J | Open Market Purchase | 26.12.2025 | 1,000,000 | +1,000,000 | $10.00 |
| GABELLI MARIO J | Other Transaction | 26.12.2025 | 500,000 | -500,000 | $10.00 |
| GABELLI MARIO J | Open Market Purchase | 26.12.2025 | 100,000 | +100,000 | $10.00 |
| GABELLI MARIO J | Open Market Purchase | 26.12.2025 | 200,000 | +200,000 | $10.00 |
| GABELLI MARIO J | Open Market Purchase | 26.12.2025 | 500,000 | +500,000 | $10.00 |
| GABELLI MARIO J | Open Market Purchase | 26.12.2025 | 100,000 | +100,000 | $10.00 |
| GABELLI MARIO J | Other Transaction | 26.12.2025 | 200,000 | -200,000 | $10.00 |
| Saba Capital Management, L.P. | Open Market Purchase | 17.12.2025 | 4,084 | +4,084 | $9.36 |
| Saba Capital Management, L.P. | Open Market Purchase | 16.12.2025 | 11,312 | +11,312 | $9.37 |
| GABELLI MARIO J | Open Market Purchase | 3.12.2025 | 2,500 | +2,500 | $9.69 |
| Saba Capital Management, L.P. | Open Market Purchase | 25.11.2025 | 14,451 | +14,451 | $9.62 |
| GABELLI MARIO J | Open Market Purchase | 30.10.2025 | 1,800,000 | +1,800,000 | $10.18 |
| VANEKRIS ANTHONIE C | Open Market Sale | 14.10.2025 | 1,000 | -1,000 | $9.12 |
| VANEKRIS ANTHONIE C | Open Market Sale | 13.10.2025 | 1,000 | -1,000 | $9.15 |
| VANEKRIS ANTHONIE C | Open Market Sale | 9.10.2025 | 1,000 | -1,000 | $9.27 |
| VANEKRIS ANTHONIE C | Open Market Sale | 8.10.2025 | 1,000 | -1,000 | $9.26 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,191 shares short as of 2026-08-31 · vs. 5,631 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
33.7% of trading volume this week was short selling, vs. 43.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology